These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18388514)

  • 61. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Disease modifying antirheumatic drugs].
    Luong Ba K; Gabay C
    Rev Med Suisse; 2014 Mar; 10(421):595-6, 598, 600-2. PubMed ID: 24701712
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New insight into rheumatoid arthritis management. The disease and the drugs used to treat it have been linked to cardiovascular disease, melanoma, and fracture.
    Duke Med Health News; 2012 Feb; 18(2):1-2. PubMed ID: 22397007
    [No Abstract]   [Full Text] [Related]  

  • 64. Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumtic drugs.
    Walker UA
    Semin Hematol; 2016 Apr; 53 Suppl 1():S58-60. PubMed ID: 27312168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combination therapy in rheumatoid arthritis.
    Goekoop YP; Allaart CF; Breedveld FC; Dijkmans BA
    Curr Opin Rheumatol; 2001 May; 13(3):177-83. PubMed ID: 11333345
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis.
    Mutlu MY; Tascilar K; Schett G
    Joint Bone Spine; 2023 Sep; 90(5):105578. PubMed ID: 37076093
    [TBL] [Abstract][Full Text] [Related]  

  • 67. AJC editor's consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease.
    Friedewald VE; Ganz P; Kremer JM; Mease PJ; O'Dell JR; Pearson TA; Ram CV; Ridker PM; Salmon JE; Roberts WC
    Am J Cardiol; 2010 Aug; 106(3):442-7. PubMed ID: 20643261
    [No Abstract]   [Full Text] [Related]  

  • 68. [New therapies in rheumatoid arthritis].
    Forster A
    Praxis (Bern 1994); 2003 Mar; 92(11):489-96. PubMed ID: 12698581
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years.
    Santiago T; da Silva JA
    Ann N Y Acad Sci; 2014 May; 1318():41-9. PubMed ID: 24814757
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis.
    Marguerie L; Flipo RM; Grardel B; Beaurain D; Duquesnoy B; Delcambre B
    Joint Bone Spine; 2002 May; 69(3):275-81. PubMed ID: 12102274
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review.
    Maese J; Díaz Del Campo P; Seoane-Mato D; Guerra M; Cañete JD
    Reumatol Clin (Engl Ed); 2018; 14(2):81-89. PubMed ID: 28089501
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Methotrexate treatment and mortality in rheumatoid arthritis.
    Slot O
    Lancet; 2002 Oct; 360(9339):1095; author reply 1097-8. PubMed ID: 12384008
    [No Abstract]   [Full Text] [Related]  

  • 73. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis.
    van Riel PL; Haagsma CJ; Furst DE
    Baillieres Best Pract Res Clin Rheumatol; 1999 Dec; 13(4):689-700. PubMed ID: 10652648
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disease-Modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry.
    Muñoz-Martínez C; Segura-Puertas M; Gómez-Moreno G
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2834-2842. PubMed ID: 33877648
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Methotrexate treatment and mortality in rheumatoid arthritis.
    Tröger U; Bode-Böger SM
    Lancet; 2002 Oct; 360(9339):1096; author reply 1097-8. PubMed ID: 12384010
    [No Abstract]   [Full Text] [Related]  

  • 76. Drug therapy for patients with rheumatoid arthritis.
    Arthur V
    Br J Nurs; 1995 Jun 8-21; 4(11):616-21. PubMed ID: 7626934
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sulfasalazine-induced immune thrombocytopenia.
    Cantarini L; Tinazzi I; Biasi D; Fioravanti A; Galeazzi M
    Postgrad Med J; 2007 Jun; 83(980):e1. PubMed ID: 17551063
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacoeconomics of long-term treatment of rheumatoid arthritis.
    Blumenauer B; Coyle D; Tugwell P
    Expert Opin Pharmacother; 2002 Apr; 3(4):417-22. PubMed ID: 11934345
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Efficacy of disease modifying anti-rheumatic drugs on bone destruction in rheumatoid arthritis].
    Tsuji H; Mimori T
    Clin Calcium; 2015 Dec; 25(12):1835-42. PubMed ID: 26608859
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis.
    Martínez-Múgica C; Salgueiro E
    Farm Hosp; 2021 Dec; 46(1):15-20. PubMed ID: 35379087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.